Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0130
0.00 (0.00%)
Jan 8, 2026, 4:00 PM EST
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $3.38M in the quarter ending September 30, 2025, a decrease of -38.34%. This brings the company's revenue in the last twelve months to $11.89M, down -41.78% year-over-year. In the year 2024, Emmaus Life Sciences had annual revenue of $16.65M, down -43.73%.
Revenue (ttm)
11.89M
Revenue Growth
-41.78%
P/S Ratio
0.07
Revenue / Employee
339.80K
Employees
35
Market Cap
830.25K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.65M | -12.94M | -43.73% |
| Dec 31, 2023 | 29.60M | 11.21M | 60.94% |
| Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
| Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
| Dec 31, 2020 | 23.17M | 415.00K | 1.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Emmaus Life Sciences News
- 9 days ago - Emmaus Life Sciences Announces Strategic Transaction - Business Wire
- 7 weeks ago - Emmaus Life Sciences Reports Quarterly Financial Results - PRNewsWire
- 5 months ago - Emmaus Life Sciences Reports Quarterly Financial Results - PRNewsWire
- 7 months ago - Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements - PRNewsWire
- 8 months ago - Emmaus Life Sciences Reports Quarterly Financial Results - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Improved Quarterly Financial Results - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Quarterly Financial Results - PRNewsWire
- 1 year ago - Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer - PRNewsWire